Answers are grounded in this paper and cite their sources.
The emergence of serotype G9 rotaviruses globally suggests that future rotavirus vaccines may need to incorporate additional specificities beyond G1-G4.
Rotaviruses are the major cause of severe gastroenteritis in young children worldwide. The first licensed human rotavirus vaccine, the rhesus rotavirus-tetravalent vaccine (RRV-TV), incorporated serotype G1, G2, G3, and G4 specificities, as these have been the four most common serotypes causing severe disease in children globally over the last 20 years (7). The RRV-TV has recently been suspended from routine use because of an association between vaccination and increased rates of intussusception among vaccine recipients (1). Recent second-generation (bovine virus-based) vaccines also include G1 to G4 specificities (2). However, the increase in reports of other rotavirus serotypes as a cause of severe diarrhea suggests that future vaccines may need to incorporate additional specificities. Serotype G9 rotaviruses have recently emerged as important human pathogens in India (9), the United States (8), Bangladesh (10), Malawi (3), the United Kingdom (M. Iturriza, J. Green, M. Ramsay, D. Brown, U. Desselberger, and J. J. Gray, Abstr. 18th Ann. Meet. Am. Soc. Virol., abstr. W43-2, p. 136, 1999; A. D. Steele and W. D. Cubitt, Abstr. 18th Ann. Meet. Am. Soc. Virol, abstr. W43-3, p. 136, 1999), and Nigeria (V. Akran, A. Mbida, J. Mwenda, J. Muyanga, L. Nimzing, J. Nyangao, G. Pennap, D. Steele, A. Trablesi, and S. Tswana, Abstr. XIth Int. Congr. Virol., abstr. VP25.11, p. 374, 1999). This has raised interest in the global distribution of this serotype in the context of the development of effective vaccine formulations.
No takes yet. Share an insight, caveat, or question.
Palombo et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: